A study tied more severe disability in progressive MS to abnormalities in cholesterol and inflammatory markers.
The FDA cleared Neurogenesis to provide NG01 to people with progressive forms of MS through an expanded access program.
An Italian registry study of 73 patients with secondary progressive multiple sclerosis found cladribine significantly lowered ...
FDA clears expanded access to NeuroGenesis Bio's investigational NG01 cell therapy for some progressive MS patients; approval ...
Few neurological diseases have seen a transformation in diagnosis and treatment as remarkable as multiple sclerosis. A ...
Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...
First patient begins the NG01 treatment process at the University of Miami today with bone marrow aspirationLAFAYETTE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeuroG Inc., a late-stage clinical ...
Heidi Crayton, MD, and Maria Lopes, MD, discuss the limitations of using relapse rates as a critical endpoint in trials for patients with non-relapsing secondary progressive multiple sclerosis ...
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...
Graviton BioScience Corporation, a clinical-stage biotechnology company developing a diverse pipeline of therapeutics including highly selective Rho-associated coiled-coil-containing protein kinase 2 ...
New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...
Multiple sclerosis has been part of New Yorker Louise Warner-Beckles' life for more than 40 years, but she is still pushing ...